Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria

重复伊维菌素大规模药物管理用于疟疾控制 II (RIMDAMAL II)：疟疾综合控制的双盲整群随机试验

• 批准号: 10468728
• 负责人: BRIAN David FOY
• 金额: $ 67.46万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10468728
• 关键词: 10 year old; Adopted; Africa; Age; Agriculture; Alleles; Amodiaquine; Anopheles Genus; Anti-malarial drug resistance; Antimalarials; Antiparasitic Agents; Artemisinins; Beds; Behavioral; Biological Assay; Bite; Blood; Burkina Faso; Cessation of life; Chemistry; Chemoprevention; Child; Childhood; Chloroquine; Clinical; Clinical Trials; Cluster randomized trial; Combined Modality Therapy; Communities; Country; Culicidae; Development; Dose; Double-Blind Method; Drops; Drug Combinations; Drug Kinetics; Drug resistance; Ensure; Entomology; Failure; Filarial Elephantiases; Future; Goals; Health; Human; Incidence; Individual; Infection; Ingestion; Insecticide Resistance; Insecticides; Intervention; Ivermectin; Link; Malaria; Measures; Monitor; Morbidity - disease rate; Mutation; Onchocerciasis; Organism; Parasite Control; Parasite resistance; Parasites; Persons; Pharmaceutical Preparations; Physiology; Plasmodium; Population; Predisposition; Pregnant Women; Prevalence; Prevention; Preventive treatment; Pyrimethamine-Sulfadoxine; Randomized Clinical Trials; Recipe; Recording of previous events; Residual state; Resistance; Resistance development; Safety; Seasons; Seminal; Southeastern Asia; Sporozoites; Sulfadoxine-pyrimethamine resistance; Testing; Time; aged; arm; artesunate; authority; base; combat; evidence base; experimental study; indexing; malaria transmission; mortality; neglected tropical diseases; neuromuscular; novel; optimism; preservation; primary endpoint; primary outcome; programs; pyrethroid; rapid diagnosis; resistance allele; success; survivorship; tool; vector; vector control

Project Summary / Abstract Enhanced malaria control efforts since the turn of the century have resulted in notable reductions in malaria morbidity and mortality. This success has been driven by the widespread distribution of long-lasting insecticide treated nets and targeted indoor residual spraying of insecticides to combat vectors as well as rapid diagnosing and treatment of malaria with artemesisin-based combination therapies, and chemoprevention programs for pregnant women and children. However, malaria control efforts are stagnating because programs targeting both the vector and the parasite are not well integrated, and the efficacy of both is severely threatened by widespread resistance of vectors to currently-approved insecticides and spreading resistance of parasites to currently- approved drugs. We hypothesize that malaria control can be enhanced, and the spread of both insecticide resistance and antimalarial drug resistance can be curtailed, if vector and parasite control efforts are linked using the endectocide ivermectin that can target both organisms with another layer of combination therapy to each. Ivermectin is an antiparasitic drug that is safe and distributed to hundreds of millions of humans each year. It also efficiently kills malaria vectors that blood feed on treated people and strong evidence suggests it also has activity against the sporogonic and exoerythrocytic stages of Plasmodium. We will conduct a cluster randomized clinical trial in Burkina Faso to test whether repeated ivermectin mass drug administrations, integrated into a monthly delivery platform with the standard malaria control measures of seasonal malaria chemoprevention and insectide-treated bed net distribution in the Sahel, will reduce childhood malaria incidence and limit resistance in both mosquitoes and parasites.

项目摘要/摘要

项目成果

Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data.

• DOI: 10.1177/17407745211028581
• 发表时间: 2021-10
• 期刊: Clinical trials (London, England)
• 作者: Jackson CL;Colborn K;Gao D;Rao S;Slater HC;Parikh S;Foy BD;Kittelson J
• 通讯作者: Kittelson J